Kartashev, VladimirDöring, MatthiasNieto, LeonardoColetta, EledaKaiser, RolfSierra, SaletaHCV EuResist Study groupGuerrero, A.Stoiber, H.Paar, C.Vandamme, A. M.Nevens, F.Ranst, M. VanCuypers, L.Braun, P.Ehret, R.Obermeier, M.Schneeweiss, S.Scholten, S.Römer, K.Isernhagen, K.Qurashi, N.Heger, E.Knops, E.Neumann-Fraune, M.Timm, J.Walker, A.Lübke, N.Wedemeyer, H.Wiesch, J. Schulze zurLütgehetmann, M.Polywka, S.Däumer, M.Hoffmann, D.Protzer, U.Marascio, N.Foca, A.Liberto, M. C.Barreca, G. S.Galati, L.Torti, C.Pisani, V.Perno, C. F.Ceccherini-Silberstein, F.Cento, V.Ciotti, M.Zazzi, M.Rossetti, A.De Luca, A.Caudai, C.Mor, O.Devaux, C.Staub, T.Araujo, F.Gomes, P.Cabanas, J.Markin, N.Khomenko, I.Govorukhina, M.Lugovskaya, G.Dontsov, D.Mas, A.Martró, E.Saludes, V.Rodríguez-Frías, F.García, F.Casas, P.Iglesia, A. de laAlados, J. C.Pena-López, M. J.Rodríguez, M. J.Galán, J. C.Suárez, A.Cardeñoso, L.Guerrero, M. D.Vegas-Dominguez, C.Blas-Espada, J.García, R.García-Bujalance, S.Benítez-Gutiérrez, L.Mendoza, C. deMontiel, N.Santos, J.Viciana, I.Delgado, A.Martínez-Sanchez, P. A.Fernández-Alonso, M.Reina, G.Trigo, M.Echeverría, M. J.Aguilera, A.Navarro, D.Bernal, S.Lozano, M. C.Fernández-Cuenca, F.Orduña, A.Eiros, J. M.Ortíz de Lejarazu, R.Martínez-Sapiña, A. M.García-Díaz, A.Haque, T.2019-12-202019-12-202016-08J Clin Virol. 2016 Aug;81:82-9. doi: 10.1016/j.jcv.2016.05.01010.1016/j.jcv.2016.05.010http://hdl.handle.net/10400.26/30652This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).BACKGROUND: HCV affects 185 million people worldwide and leads to death and morbidities. HCV has a high genetic diversity and is classified into seven genotypes and 67 subtypes. Novel anti-HCV drugs (Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT). OBJECTIVES: Analysis of epidemiological information and viral GT from patients undergoing viral genotyping in 2011-2015. STUDY DESIGN: Anonymized information from 52 centers was analyzed retrospectively. RESULTS: 37,839 samples were included in the study. We show that the GT distribution is similar throughout Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of the recombinant genotype P were reported in Munich (Germany). In addition, we observed that GT proportion was dependant on patientś gender, age and transmission route: GTs 1b and 2 were significantly more common in female, older, nosocomially-infected patients, while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume, and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed. In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was significantly associated with higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively). CONCLUSION: Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveillance is necessary to better assess hepatitis C infection in Europe and to take appropriate actionsengGenotypeHCVHepatitis C virusMolecular epidemiologyTransmissionjournal article10.1016/j.jcv.2016.05.010